A Deal That Split One Company Into Two Strategies
Catalent Pharma Solutions, long one of the world's largest contract development and manufacturing organizations, no longer answers to a single master. In February 2024, Novo Holdings, the controlling shareholder of Novo Nordisk, agreed to acquire Catalent outright for approximately 16.5 billion dollars. The transaction closed in December 2024 after clearing antitrust review in the United States and European Union, but the more consequential piece came bundled inside it: simultaneous with the close, Novo Nordisk itself acquired three Catalent fill-finish sites, in Anagni, Italy; Brussels, Belgium; and Bloomington, Indiana, for roughly 11 billion dollars. The rest of Catalent, spanning biologics, gene therapy, softgel and oral solid dose manufacturing, remained a Novo Holdings portfolio company operating at arm's length, still serving third-party pharma clients.
That structure matters because it converts a chunk of contract manufacturing capacity that used to serve the whole industry into dedicated Novo Nordisk supply for semaglutide, the molecule behind Ozempic and Wegovy. Novo Nordisk had already been leasing capacity at these sites to fill pens and vials amid a demand surge that outstripped its own network. Buying the plants outright removes lease renewal risk and gives Novo Nordisk direct control over sterile fill-finish lines it had previously accessed only as a customer.
The Footprint That Remains
Catalent's directory profile lists 22 registered manufacturing sites and 261 associated NDC-linked products, reflecting a business built on breadth rather than a single blockbuster. Its facility in Harmans, Maryland, acquired through the 2019 purchase of Paragon Bioservices, anchors its viral vector and gene therapy manufacturing, a segment Catalent expanded aggressively as AAV-based therapies moved toward commercial approval. Its Winston-Salem, North Carolina campus houses proprietary softgel and oral drug delivery technology dating to the original R.P. Scherer lineage. Beyond these anchor sites, Catalent's network covers biologics drug substance and drug product manufacturing, clinical supply packaging, and analytical services across North America, Europe and Asia.
The three divested fill-finish plants were among Catalent's highest-profile sterile injectable assets, and their departure narrows the company's footprint in exactly the segment that had made it indispensable to GLP-1 manufacturers. What remains is a CDMO more concentrated in biologics and cell and gene therapy work, areas where Novo Holdings has separately been building exposure through its broader life sciences investment arm.
Quality History and the Capacity Squeeze
Catalent's run-up to the acquisition was not free of regulatory friction. The company disclosed manufacturing and compliance issues at several sites in 2023, including delays tied to quality remediation work that pushed back timelines for customers awaiting fill-finish slots, at a moment when GLP-1 demand was already straining the entire injectable supply chain. Those disclosures coincided with a period of financial strain at Catalent and contributed to the strategic logic behind selling to a well-capitalized owner with a direct stake in guaranteeing throughput.
For Novo Nordisk, the fill-finish sites solve a real constraint. Sterile injectable capacity, particularly for prefilled pens and cartridges, requires specialized isolators, filling lines and packaging equipment that cannot be stood up quickly. Owning Anagni, Brussels and Bloomington outright gives Novo Nordisk incremental control over semaglutide output at a time when Eli Lilly's tirzepatide franchise, marketed as Mounjaro and Zepbound, is capturing share in the same incretin category and both companies are racing to expand capacity faster than rivals.
Competitive Position in a Crowded CDMO Field
The remaining Catalent still competes in a market crowded with scaled players. Thermo Fisher Scientific's Patheon Manufacturing Services, which the directory shows operating 19 sites and 303 products, competes directly in oral solid dose and sterile fill-finish work. Lonza remains the largest independent biologics CDMO by revenue, WuXi Biologics continues to expand its 18-site network despite the overhang of proposed BIOSECURE Act restrictions on Chinese biomanufacturers, and Samsung Biologics has been aggressively adding large-scale bioreactor capacity in South Korea. Against that field, Catalent's differentiation now rests less on scale and more on specialized technical capability, gene therapy vector production, softgel formulation science, and complex biologics fill-finish for customers outside the Novo Nordisk orbit.
The open question for the industry is whether Novo Holdings will run Catalent as a genuinely independent CDMO available to competitors, including other GLP-1 developers, or whether ownership by the parent of Novo Nordisk will chill business from rivals wary of sharing proprietary manufacturing data with a company under common ownership with a direct competitor. Regulators extracted behavioral commitments during antitrust review specifically to address this concern, requiring firewalls between Catalent's commercial operations and Novo Nordisk's product teams, but customer perception often lags formal governance structures.
What Comes Next
The Catalent transaction is a template worth watching. As GLP-1 demand, cell and gene therapy commercialization, and biologics manufacturing all compete for the same limited pool of sterile fill-finish and specialized bioprocessing capacity, expect more originator companies to bypass the traditional CDMO relationship altogether and buy plants directly, as Novo Nordisk did, rather than compete for capacity through long-term supply agreements. Eli Lilly has already committed more than 20 billion dollars to new manufacturing sites in Indiana, Wisconsin and internationally, largely built in-house rather than outsourced, suggesting the largest incretin players increasingly see contract manufacturing dependence as a strategic liability rather than a cost-saving convenience.
For the remainder of the CDMO industry, that trend cuts two ways. It may shrink the addressable market for large-molecule fill-finish work as top-tier originators internalize capacity, while simultaneously increasing demand from mid-size biotechs and gene therapy developers who cannot justify building their own plants and will need independent partners like the newly configured Catalent, Lonza and Samsung Biologics even more. How Novo Holdings balances Catalent's dual identity, part captive supplier, part open-market CDMO, will be a useful signal for whether vertical integration or outsourcing wins the next phase of biologics manufacturing economics.